Clinical Trial

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-12
Trial Details
NCT Number NCT07496450
Lead Sponsor ModernaTX, Inc.
Conditions Influenza
Enrollment 4,050 participants
Start Date 2026-03-23
Primary Completion 2027-01-28 (estimated)
Study Completion 2027-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-11